Document is current
Any future updates will be listed below
-
Authors
Noer, Maya G.
Christensen, Kimmie B. https://orcid.org/0000-0001-7255-3139
Mikkelsen, Nanna S.
Skjelbostad, Sigrid Fu
Rothemejer, Frederik H.
Wittenborn, Thomas
Fammé, Simon
Mikkelsen, Kasper
Barington, Torben https://orcid.org/0000-0001-6968-148X
Thomsen, Martin K.
Barnkob, Mike B. https://orcid.org/0000-0002-5892-1174
Møller, Bjarne K.
Bak, Rasmus O. https://orcid.org/0000-0002-7383-0297
-
Funding
Funding for this research was provided by:
Landmand af Ølufgård Peder Nielsen Kristensen’s Memorial Fund
The Danish health authorities (4-1612-391/1)
HORIZON EUROPE European Research Council (101041231)
Horizon 2020 (101057438)
Lundbeck Foundation (R238-2016-3349)
Novo Nordisk Fonden (NNF19OC0058238)
Innovationsfonden (8056-00010B)
Carlsbergfondet (CF20-0424)
Agnes og Poul Friis Fond
Slagtermester Max Wørzner og Hustru Inger Wørzners Mindelegat
A.P. Møller og Hustru Chastine Mc-Kinney Møllers Fond til almene Formaal
Riisfort Fonden
- License Information
-
More Information
Article History
Received: 3 October 2025
Accepted: 8 July 2026
First Online: 24 July 2026
Declarations
Ethics approval and consent to participate: PBMCs were obtained from healthy donors at the Blood Bank of Aarhus University Hospital. Buffy coats were provided as de-identified donor material, and no identifiable personal or clinical data were available to the researchers. According to Danish law, the use of anonymized buffy coats does not require specific ethical approval. All animal experiments were approved by the Danish Animal Experiments Inspectorate (approval 2023–15-0201–01407 and 2021–15-0201–00922).
Consent for publication: Not applicable.
Competing interests: ROB holds equity in Kamau Therapeutics and UNIKUM Therapeutics and is a cofounder of UNIKUM Therapeutics. Neither company was involved in the present study. ROB is an inventor on patents and patent applications related to CRISPR/Cas and cellular therapies. ROB reports research funding from Novo Nordisk. The other authors declare no competing interests.
